Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 2 · 50%

Anti‐PD1 monoclonal antibodies vs anti‐CTLA4 monoclonal antibodies

Progression‐free survival · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to lower progression‐free survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.54 [0.5, 0.6]
1465 participants
High

Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies

Progression‐free survival · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies with leads to lower progression‐free survival† compared with without anti‐PD1 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.4 [0.35, 0.46]
738 participants
High

Anti‐PD1 monoclonal antibodies vs chemotherapy alone

Progression‐free survival · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.49 [0.39, 0.61]
957 participants
Moderate

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Progression‐free survival · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.76 [0.63, 0.92]
502 participants
Moderate